About Equilibrative nucleoside transporter 2
Equilibrative nucleoside transporter 2 (SLC29A2) is a protein
from Homo sapiens identified by UniProt accession
Q14542, 456 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | Equilibrative nucleoside transporter 2 |
| UniProt accession | Q14542 |
| Gene | SLC29A2 |
| Organism | Homo sapiens |
| Length | 456 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (67)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.27
- handedness · score 0.13
- cutaneous melanoma · score 0.12
- urate measurement · score 0.07
- C-reactive protein measurement · score 0.06
- gestational diabetes · score 0.06
- serum metabolite measurement · score 0.05
- BMI-adjusted waist circumference · score 0.04
- BMI-adjusted waist-hip ratio · score 0.04
- self reported educational attainment · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14542-F1 | alphafold | PREDICTED | 84.19 | — |
Amino-acid sequence (456 residues)
MARGDAPRDS YHLVGISFFI LGLGTLLPWN FFITAIPYFQ ARLAGAGNST ARILSTNHTG PEDAFNFNNW VTLLSQLPLL LFTLLNSFLY QCVPETVRIL GSLLAILLLF ALTAALVKVD MSPGPFFSIT MASVCFINSF SAVLQGSLFG QLGTMPSTYS TLFLSGQGLA GIFAALAMLL SMASGVDAET SALGYFITPC VGILMSIVCY LSLPHLKFAR YYLANKSSQA QAQELETKAE LLQSDENGIP SSPQKVALTL DLDLEKEPES EPDEPQKPGK PSVFTVFQKI WLTALCLVLV FTVTLSVFPA ITAMVTSSTS PGKWSQFFNP ICCFLLFNIM DWLGRSLTSY FLWPDEDSRL LPLLVCLRFL FVPLFMLCHV PQRSRLPILF PQDAYFITFM LLFAVSNGYL VSLTMCLAPR QVLPHEREVA GALMTFFLAL GLSCGASLSF LFKALL
Explore Equilibrative nucleoside transporter 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets